NBI-921352 Emerging Drug Insight

“NBI-921352 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about NBI-921352 for Developmental and Epileptic Encephalopathy in the 7MM. A detailed picture of the NBI-921352 for Developmental and Epileptic Encephalopathy in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the NBI-921352 for Developmental and Epileptic Encephalopathy. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the NBI-921352 market forecast, analysis for Developmental and Epileptic Encephalopathy in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Developmental and Epileptic Encephalopathy.

Drug Summary

NBI-921352 (XEN901) is a potent, highly selective Nav1.6 sodium channel inhibitor, which is being developed to treat pediatric patients with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) and other potential indications, including adult focal epilepsy.

Neurocrine Biosciences is conducting the KAYAK Phase II study to assess the efficacy, safety, tolerability, and pharmacokinetics of NBI-921352 as adjunctive therapy in patients (2–21 years of age) with SCN8A-DEE. After completing the KAYAK study, eligible participants may have the option to enroll in our open-label extension study to evaluate the long-term safety and tolerability of NBI-921352 in patients with SCN8A-DEE.

Neurocrine Biosciences is also developing NBI-921352 for the potential treatment of focal-onset seizures, with data expected in 2023.

Scope of the Report

The report provides insights into:

•  A comprehensive product overview including the NBI-921352 description, mechanism of action, dosage and administration, research and development activities in Developmental and Epileptic Encephalopathy.
•  Elaborated details on NBI-921352 regulatory milestones and other development activities have been provided in this report.
•  The report also highlights the NBI-921352 research and development activity in Developmental and Epileptic Encephalopathy details across the United States, Europe and Japan.
•  The report also covers the patents information with expiry timeline around NBI-921352.
•  The report contains forecasted sales of NBI-921352 for Developmental and Epileptic Encephalopathy till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for Developmental and Epileptic Encephalopathy.
•  The report also features the SWOT analysis with analyst views for NBI-921352 in Developmental and Epileptic Encephalopathy.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

NBI-921352 Analytical Perspective by DelveInsight

• In-depth NBI-921352 Market Assessment

This report provides a detailed market assessment of NBI-921352 in Developmental and Epileptic Encephalopathy in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

• NBI-921352 Clinical Assessment

The report provides the clinical trials information of NBI-921352 for Developmental and Epileptic Encephalopathy covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

•  In the coming years, the market scenario for Developmental and Epileptic Encephalopathy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
•  The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence NBI-921352 dominance.
•  Other emerging products for Developmental and Epileptic Encephalopathy are expected to give tough market competition to NBI-921352 and launch of late-stage emerging therapies in the near future will significantly impact the market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of NBI-921352 in Developmental and Epileptic Encephalopathy.
•  Our in-depth analysis of the forecasted sales data of NBI-921352 from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the NBI-921352 in Developmental and Epileptic Encephalopathy.

Key Questions

•  What is the product type, route of administration and mechanism of action of NBI-921352?
•  What is the clinical trial status of the study related to NBI-921352 in Developmental and Epileptic Encephalopathy and study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing and other activities related to the NBI-921352 development?
•  What are the key designations that have been granted to NBI-921352 for Developmental and Epileptic Encephalopathy?
•  What is the forecasted market scenario of NBI-921352 for Developmental and Epileptic Encephalopathy?
•  What are the forecasted sales of NBI-921352 in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
•  What are the other emerging products available in Developmental and Epileptic Encephalopathy and how are they giving competition to NBI-921352 for Developmental and Epileptic Encephalopathy?
•  Which are the late-stage emerging therapies under development for the treatment of Developmental and Epileptic Encephalopathy?